Tongjitang Chinese Medicines Company, a Chinese specialty pharmaceutical company, has reported a net loss of RMB79.26m, or RMB0.59 per share, for the fourth quarter of 2008, compared to
Highlights of the fourth quarter of 2008 and recent weeks include: Introducing the company’s first three cancer diagnostic tests in the US, miRview mets, miRview squamous and miRview
Wyeth has reported that its Prevenar has been added to Saudi Arabia’s national childhood immunization program to help protect infants and young children from pneumococcal disease – said
A total of approximately 395.7 million shares of Genentech common stock were tendered representing 84.7% of Genentech’s publicly held shares. Roche Investments USA has accepted for payment all
Caldera’s products include the Desara sling system for treating stress urinary incontinence. Encision will use its sales employees to supplement Caldera’s sales team in introducing Caldera’s products to
According to IH Systems, Robotic IV Automation (RIVA) system is a self-contained unit for filling IV syringes and bags. Kevin McGarry, CEO of IH Systems, said: “We are
Eli Lilly and Company has reported promising new data from Phase III Next trial which showed that arzoxifene, an investigational selective estrogen receptor modulator, was superior to raloxifene
For the year ended December 31, 2008, the company reported a net loss of $28.15 million, or $1.42 per share, compared to a net loss of $28.1 million,
The company reported net revenues of C$2 million for the first quarter of 2009, compared to C$599,000 for the same period of 2008. Luc Tanguay, senior executive vice
Zemiva is a molecular imaging radiopharmaceutical the company is developing to detect cardiac ischemia, the lack of sufficient blood flow to the heart. In this trial, the combination
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.